• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk

    9/16/24 1:04:00 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GSK alert in real time by email
    • Brooke Shields convenes other celebrities, influencers and patient advocates over 50 to discuss the power of aging and how to protect their health
    • Shields directs a short film, encouraging adults 50 years of age and older to talk to their doctor or pharmacist about their risk for shingles — a disease that affects about 1 million people annually in the US — and about vaccination
    • The partnership is part of GSK's national THRIVE@50+ campaign

    PHILADELPHIA, Sept. 16, 2024 /PRNewswire/ -- GSK plc (NYSE:GSK) is partnering with Brooke Shields, as part of its THRIVE@50+ campaign, to encourage people 50 and older to embrace and protect the power they've found in aging by asking their doctor or pharmacist about their risk for shingles and about vaccination.

    Experience the full interactive Multichannel News Release here: https://www2.multivu.com/gsk/9290451-en-brooke-shields-gsk-shingles-risk-adults-50-and-older

    Shields exemplifies what it means to thrive at any age, including now, at her current age of 59. The actress, TV personality, model and entrepreneur now adds fierce health advocate to her resume. Like so many others her age, at a time when Shields was stepping into a new, unapologetic power, she also learned that with age comes the important lesson of protecting one's health from vulnerabilities like shingles. In fact, 99% of people over the age of 50 are at risk for developing shingles, although not everyone will.1

    Brooke Shields said: "For so long, we've been conditioned to fear aging, but the reality is that age is power. As I've gotten older, my life experiences have really solidified who I am and what I stand for, and when I talked to other women who were a part of this campaign, it's clear that I'm not the only one who feels this way. The unfair twist is that just as we've reached this time of our lives where we feel like the best version of ourselves, we're also experiencing new health risks. When I learned that people over 50 are at an increased risk for shingles, I couldn't help myself from starting the conversation. This matters because our power is worth protecting."

    Part of Shields' partnership with GSK's THRIVE@50+ campaign involved her directing and producing videos with other influential women who are thriving in their 50s and beyond, including football mom Donna Kelce, actress Gina Torres, reality TV star Susan Noles and former shingles patients, among others, each sharing their own unique stories and radiating the power they've come into with age. World-renowned fashion and lifestyle photographer Pamela Hanson joined the group to capture that power in her iconic portrait style.

    Leah Smith, PharmD, GSK medical educator, said: "Shingles can be an isolating experience that can also really take a toll on one's quality of life. And it's not as uncommon as you might think — every year, there are about one million cases of shingles in the US alone. Age is the most important risk factor for shingles, so anyone over 50 should consider asking their doctor or pharmacist about shingles and about vaccination."

    GSK's goal with their THRIVE@50+ campaign is to create a cultural movement around healthy aging, grounded in the genuine and authentic experiences that bring the community together.

    About THRIVE@50+

    THRIVE@50+ is a national public health initiative from GSK to educate people 50 and older about their risk for shingles, due to the natural aging of the immune system, and the impact the disease can have on everyday life. We encourage people 50 and older to understand how they can help prevent shingles, like asking their doctor or pharmacist about their risk of shingles and about vaccination, so they can stay ahead of this health challenge and continue to thrive.

    About shingles

    Shingles is caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox.1 By age 50, VZV is present in most adults2 and may reactivate with advancing age.3 As people age, the strength of the immune system's response to infection wanes, increasing the risk of developing shingles.1

    Shingles typically presents as a rash, with painful blisters across the chest, abdomen or face.3 The pain is often described as aching, burning, stabbing or shock-like.4

    Following the rash, a person may experience post-herpetic neuralgia (PHN), a long-lasting nerve pain that can last weeks or months and occasionally persists for several years.4 PHN is the most common complication of shingles, occurring in 5–30% of all shingles cases, from findings in various studies.5

    About GSK

    GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

    Cautionary statement regarding forward-looking statements

    GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q2 Results for 2024.

    Registered in England & Wales:

    No. 3888792

    Registered Office:

    79 New Oxford Street

    London

    WC1A 1DG

    References:

    1. CDC. Shingles (Herpes Zoster): Clinical Overview. Available at: https://www.cdc.gov/shingles/hcp/clinical-overview/
    2. Johnson RW, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109-120.
    3. Mueller NH, et al. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease and latency. Neurologic Clinics. 2008;26;675-697.
    4. Cheng J, Rosenquist RW. Herpes zoster and postherpetic neuralgia. Fundamentals of Pain Medicine. 2018:221-5.
    5. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833. doi: 10.1136/bmjopen-2014-0048

     

    Gina Torres

     

    Cision View original content:https://www.prnewswire.com/news-releases/brooke-shields-partners-with-gsk-to-educate-adults-50-and-older-about-their-shingles-risk-302249282.html

    SOURCE GSK

    Get the next $GSK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GSK

    DatePrice TargetRatingAnalyst
    1/27/2026Neutral
    Citigroup
    1/6/2026Equal Weight → Underweight
    Barclays
    11/25/2025Underperform → Neutral
    BofA Securities
    6/3/2025Buy → Hold
    Berenberg
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    2/12/2025Equal-Weight
    Morgan Stanley
    11/15/2024Buy → Hold
    Deutsche Bank
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    More analyst ratings

    $GSK
    SEC Filings

    View All

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    3/17/26 2:36:15 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    3/17/26 7:20:46 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    3/16/26 8:19:44 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on GlaxoSmithKline

    Citigroup initiated coverage of GlaxoSmithKline with a rating of Neutral

    1/27/26 8:46:26 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlaxoSmithKline downgraded by Barclays

    Barclays downgraded GlaxoSmithKline from Equal Weight to Underweight

    1/6/26 11:51:57 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlaxoSmithKline upgraded by BofA Securities

    BofA Securities upgraded GlaxoSmithKline from Underperform to Neutral

    11/25/25 8:32:06 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

    In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection1* GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has expanded the approved age indication of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18 to 49 years at increased risk for lower respiratory tract disease (LRTD) caused by RSV. AREXVY was previously approved in the US for the prevention of RSV-related LRTD in adults aged 60 and older, and adults aged 50–59 at increased risk for LRTD caused by RSV. This vaccine is not for use in pregnant individuals. Sanjay Gurunathan, GSK Head of Vaccines and Infectious Diseases Re

    3/13/26 11:44:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Myriad Venture Partners Expands Executive Advisory Board as Enterprise AI Moves Into Production

    Executive Advisory Board now includes more than 30 senior leaders from Fortune 500 and global enterprisesNEW YORK, March 11, 2026 /PRNewswire/ -- Myriad Venture Partners ("Myriad"), an early-stage venture capital firm focused on defining the future of business solutions in enterprise AI, enterprise B2B software, and industrial transformation, today announced the expansion of its Executive Advisory Board, bringing the Board to more than 30 C-suite leaders from Fortune 500 and global enterprises. New executives joining the Board include leaders from GSK, Mastercard, Harley-Davidson, Meta, Oracle, and other global companies, further strengthening Myriad's hands-on model and deepening its ties t

    3/11/26 6:00:00 AM ET
    $AON
    $GSK
    $HOG
    Specialty Insurers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

    Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas Bora Pharmaceuticals Co., Ltd. (("Bora", TWSE: 6472, OTCQX:BORAY), a global leader in pharmaceutical manufacturing, and GSK (LSE/NYSE:GSK) have signed a strategic agreement to renew a five-year manufacturing partnership. Bora purchased the Mississauga facility from GSK in 2020. This renewed collaboration reinforces the long-standing relationship between the two companies and expands the partnership, allowing GSK access to multiple sites within the Bora network, including its newest oral solid dose (OSD) site i

    2/23/26 1:13:00 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: GLAXOSMITHKLINE PLC converted options into 700,772 units of Common Stock and bought $4,950,000 worth of Common Stock (275,000 units at $18.00)

    4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

    7/6/21 4:38:14 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by GLAXOSMITHKLINE PLC

    3 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

    7/6/21 4:22:59 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: GLAXOSMITHKLINE PLC converted options into 30,253,189 units of Common Stock

    4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

    6/23/21 6:14:59 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    Leadership Updates

    Live Leadership Updates

    View All

    GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

    Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

    5/9/25 9:00:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

    TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

    11/18/24 7:30:00 AM ET
    $GSK
    $MDCX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    Financials

    Live finance-specific insights

    View All

    Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

    Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include

    8/6/24 4:05:00 PM ET
    $GSK
    $MYGN
    $PSNL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Medical Specialities

    GSK and CureVac to Restructure Collaboration into New Licensing Agreement

    GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA

    7/3/24 2:40:00 AM ET
    $CVAC
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Reports Third Quarter Fiscal 2024 Financial Results

    SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7 million in the third quarter of fiscal 2024, compared to $66.9 million in the third quarter of fiscal 2023, a decrease of approximately 33% due to lower research revenue after the conclusion of the GSK collaboration exclusivity term in July 2023 and lower PGS kit volumes.Announced a non-exclusive data license with GSK plc (NYSE:GSK) for novel drug target discovery and other research. U

    2/7/24 4:01:00 PM ET
    $GSK
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GSK plc

    SC 13G/A - GSK plc (0001131399) (Subject)

    11/12/24 4:32:59 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by GSK plc (Amendment)

    SC 13G/A - GSK plc (0001131399) (Subject)

    2/13/24 1:37:25 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by GSK plc (Amendment)

    SC 13G/A - GSK PLC (0001131399) (Subject)

    2/14/23 1:54:01 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care